Do statins protect the kidney as well as the heart?

Nephrology Dialysis Transplantation

Volumn 21, Issue 11, 2006, Pages 3005-3006

  Tonelli, Marcello ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NONE   (Canada)

Author keywords

CKD; PREVEND study; Statins

Indexed keywords

ALBUMIN; EZETIMIBE; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ALBUMINURIA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; DRUG INDICATION; GLOMERULUS FILTRATION RATE; HEART PROTECTION; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MEDICAL DECISION MAKING; METHODOLOGY; MORTALITY; MOTIVATION; NOTE; OBSERVATIONAL STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SELECTION; PRESCRIPTION; PRIORITY JOURNAL; RENAL PROTECTION; RISK BENEFIT ANALYSIS; RISK REDUCTION; SAMPLE SIZE; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANIMALS; DYSLIPIDEMIAS; HEART DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES;

EID: 33749994354     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl505     Document Type: Note

References (14)

1. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278
2. Schaeffner ES, Kurth T, Curhan GC et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084
3. Afzali B, Haydar AA, Vinen K, Goldsmith DJ. From Finland to fatland: beneficial effects of statins for patients with chronic kidney disease. J Am Soc Nephrol 2004; 15: 2161-2168
4. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: A meta-analysis. J Am Soc Nephrol 2006; 17: 2006-2016
5. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: The effect of statins on albuminuria. Ann Intern Med 2006; 145: 117-124
6. Atthobari J, Brantsma AH, Gansevoort RT et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: Results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant 2006
7. Asselbergs FW, Diercks GF, Hillege HL et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809-2816
8. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14: 1605
9. Zoja C, Corna D, Camozzi D et al. How to fully protect the kidney in a severe model of progressive nephropathy: A multidrug approach. J Am Soc Nephrol 2002; 13: 2898
10. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med JID-0255562 1998; 339: 584
11. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010
12. Paniagua R, Amato D, Vonesh E et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307-1320
13. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003; Suppl 2: S207-S210
14. Tonelli M, Isles C, Curhan GC et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004; 110: 1557